38 results
8-K
EX-99.1
VRDN
Viridian Therapeutics Inc
27 Feb 24
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
4:07pm
the Viridian team for their commitment throughout this past year as we work towards our mission of delivering potential best-in-class medicines for patients
S-3ASR
EX-10.1
VRDN
Viridian Therapeutics Inc
30 Nov 23
Automatic shelf registration
4:05pm
Officer
E-mail: legal@viridiantherapeutics.com
With a copy to:
Gibson, Dunn & Crutcher LLP
555 Mission Street, Suite 3000
San Francisco, CA 94105
S-3ASR
VRDN
Viridian Therapeutics Inc
30 Nov 23
Automatic shelf registration
4:05pm
C. Berns
Melanie E. Neary
Gibson, Dunn & Crutcher LLP
555 Mission Street, Suite 3000
San Francisco, CA 94105
(415) 393-8373
Thomas Beetham
Chief
8-K
EX-10.1
n3j qxjg8pku3n
30 Oct 23
Entry into a Material Definitive Agreement
8:35am
S-3ASR
fnd 1v32hw6
24 Jul 23
Automatic shelf registration
4:06pm
8-K
EX-99.1
cw0gw odz3wh
17 Jul 23
Regulation FD Disclosure
7:06am
8-K
EX-99.1
dp23k7opy3pca55yli
10 Jul 23
Regulation FD Disclosure
5:13pm
8-K
EX-99.1
wogdi qia7g
9 May 23
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:10pm
S-3ASR
EX-1.2
1ixzu lf0vw8qmm2c5
9 Sep 22
Automatic shelf registration
4:05pm
S-3ASR
n5lxnj0p8hjw
9 Sep 22
Automatic shelf registration
4:05pm
8-K
EX-1.1
6qir7qvyfpeaknslsuc
19 Aug 22
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-99.4
rlj0ktn9
15 Aug 22
Viridian Therapeutics Reports Second Quarter 2022
7:07am
8-K
EX-1.1
xgch81f xncmtsuz
23 Sep 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-5.1
v6d2gvf f4
23 Sep 21
Entry into a Material Definitive Agreement
4:30pm